Receptor, Platelet-Derived Growth Factor alpha
"Receptor, Platelet-Derived Growth Factor alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.
Descriptor ID |
D020796
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.900.500 D12.776.543.750.060.625.300 D12.776.543.750.750.400.630.300
|
Concept/Terms |
Receptor, Platelet-Derived Growth Factor alpha- Receptor, Platelet-Derived Growth Factor alpha
- CD140a Antigen
- Antigen, CD140a
- CD140a Antigens
- PDGF alpha Receptor
- PDGFR2
- PDGFRalpha
- Platelet-Derived Growth Factor alpha Receptor
- Platelet Derived Growth Factor alpha Receptor
- Receptor, PDGF alpha
- Antigens, CD140a
- PDGF-R-alpha
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Platelet-Derived Growth Factor alpha".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptors, Platelet-Derived Growth Factor [D08.811.913.696.620.682.725.400.900]
- Receptor, Platelet-Derived Growth Factor alpha [D08.811.913.696.620.682.725.400.900.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.060.625]
- Receptor, Platelet-Derived Growth Factor alpha [D12.776.543.750.060.625.300]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Platelet-Derived Growth Factor [D12.776.543.750.750.400.630]
- Receptor, Platelet-Derived Growth Factor alpha [D12.776.543.750.750.400.630.300]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Platelet-Derived Growth Factor alpha".
This graph shows the total number of publications written about "Receptor, Platelet-Derived Growth Factor alpha" by people in this website by year, and whether "Receptor, Platelet-Derived Growth Factor alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2016 | 0 | 1 | 1 | 2017 | 0 | 1 | 1 | 2018 | 1 | 0 | 1 | 2020 | 4 | 1 | 5 | 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Platelet-Derived Growth Factor alpha" by people in Profiles.
-
Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 12 01; 27(23):6333-6342.
-
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
-
Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021 04; 26(4):e622-e631.
-
Avolio E, Mangialardi G, Slater SC, Alvino VV, Gu Y, Cathery W, Beltrami AP, Katare R, Heesom K, Caputo M, Madeddu P. Secreted Protein Acidic and Cysteine Rich Matricellular Protein is Enriched in the Bioactive Fraction of the Human Vascular Pericyte Secretome. Antioxid Redox Signal. 2021 05 20; 34(15):1151-1164.
-
Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
-
Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol. 2020 10 01; 38(28):3294-3303.
-
Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 07; 21(7):935-946.
-
Smrke A, Gennatas S, Huang P, Jones RL. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol. 2020 Aug; 16(22):1639-1646.
-
Antoniou G, Lee ATJ, Huang PH, Jones RL. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|